In one sentence
A Cochrane review of dozens of studies covering about 14.7 million children found MMR highly effective against measles and mumps, with some rare short-term risks, and evidence that did not support a link to autism.
What the researchers did
Review authors synthesised comparative studies of MMR versus no vaccine, placebo, or other antigen combinations in children up to 15 years. They included five randomised trials, one controlled clinical trial, and many observational designs (cohort, case–control, time-series, and related designs) assessing effectiveness and safety. Findings below rewrite their results in plain language — not a copy of Cochrane’s plain-language summary.
What they found
- One MMR dose was at least about 95% effective against clinical measles and about 92% effective against secondary cases in household contacts.
- Mumps protection varied by strain and doses (roughly 69–81% for one Jeryl Lynn dose; higher with two doses in cited estimates; Urabe-containing vaccines also showed substantial protection).
- They did not identify studies assessing MMR effectiveness against rubella in this update.
- Exposure to MMR was judged unlikely to be associated with autism, and also unlikely for several other chronic conditions listed in the review (including asthma, leukaemia, type 1 diabetes, and Crohn’s disease in the summarised evidence).
- Short-term risks reported included higher rates of febrile seizures in windows after vaccination and higher risk of thrombocytopenic purpura within about six weeks in some studies; aseptic meningitis risk was linked mainly to Urabe and Leningrad–Zagreb strains (not the strains commonly used in many current schedules).
What this means for families and therapists
- For parents worried that MMR causes autism: this large evidence review did not support that link.
- Discuss personal medical history (prior seizures, immune conditions) with a paediatrician; rare side effects are real even when autism is not.
- Therapists can answer vaccine–autism questions with cautious, evidence-based language and refer medical decisions to clinicians.
Limitations and what we don't know yet
- Many safety studies had weak design or reporting; authors themselves called pre- and post-marketing safety reporting largely inadequate.
- Effectiveness evidence is often observational rather than randomised.
- Rubella effectiveness was not assessed in included studies.
- Formulations and strain use change by country and era; local schedules may differ from the evidence mix reviewed in 2012.
This is a plain-language summary of Vaccines for measles, mumps and rubella in children by Demicheli V., Rivetti A., Debalini M.G. et al., Cochrane Database of Systematic Reviews (2012). Source license: CC-BY-NC-4.0. It is not medical advice — talk to a qualified clinician before changing therapy.